Ixo-vec Intravitreal Gene Therapy for Neovascular AMD: 3-Year Results from the Phase 1 OPTIC Extension Trial and Preliminary Data from the Phase 2 LUNA Trial

Adverum Biotechnologies Inc. published this content on November 04, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 10, 2025 at 10:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]